Lv11
30 积分 2023-07-22 加入
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
2小时前
待确认
[Interpretation on the report of global cancer statistics 2022]
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
4个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
4个月前
已完结
Recommendations for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy
5个月前
已完结
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance
7个月前
已完结
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
7个月前
已完结
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
7个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
8个月前
已完结
Cancer incidence and mortality in China, 2022
8个月前
已完结
皖公网安备34019202002308
